Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed By T Cell Add-Back For Hematological Malignancies - Effect Of Irradiated Donor Lymphocytes On Chimerism

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Diagnosis of any of the following hematologic malignancies:

- Chronic myelogenous leukemia (CML) in chronic phase meeting 1 of the following
criteria:

- Under 41 years of age with no prior imatinib mesylate therapy

- 10 to 55 years of age and failed prior imatinib mesylate therapy

- 41 to 55 years of age for whom imatinib mesylate is not the treatment of
choice

- CML in accelerated phase or blast transformation

- Acute lymphoblastic leukemia meeting any of the following criteria:

- Over 18 years of age and in first remission with high-risk features (e.g.,
WBC greater than 100,000/mm^3, karyotypes t[9;22], t[4], t[19], t[11], and
biphenotypic leukemia)

- Second or subsequent remission

- Primary induction failure

- Partially responding or untreated relapse

- Acute myeloid leukemia meeting any of the following criteria:

- First remission, except with good-risk karyotypes (e.g., M3 t[15;17], M4E0
inv[16], t[8;21])

- Second or subsequent remission

- Primary induction failure

- Resistant relapse

- Myelodysplastic syndromes of any of the following types:

- Refractory anemia (RA) with transfusion dependence

- RA with excess blasts

- In transformation to acute leukemia

- Chronic myelomonocytic leukemia

- Myeloproliferative disorders in transformation to acute leukemia, of any of the
following types:

- Myelofibrosis

- Polycythemia vera

- Essential thrombocythemia

- Chronic lymphocytic leukemia that is refractory to fludarabine with 1 of the
following:

- Bulky progressive disease

- Thrombocytopenia (WBC no greater than 100,000/mm^3)*

- Anemia (hemoglobin no greater than 10 g/dL)* NOTE: *Not due to recent
chemotherapy

- Non-Hodgkin's lymphoma, including mantle cell lymphoma, relapsing or refractory
to current chemotherapy and monoclonal antibody therapy and unsuitable for
autologous stem cell transplantation

- Availability of a HLA-identical (6/6) family donor

PATIENT CHARACTERISTICS:

Age

- 10 to 55

Performance status

- ECOG 0-1

Life expectancy

- Not specified

Hematopoietic

- See Disease Characteristics

Hepatic

- Bilirubin no greater than 4 mg/dL

- Transaminases no greater than 3 times upper limit of normal

Renal

- Creatinine no greater than 3 mg/dL

Cardiovascular

- LVEF at least 40% of predicted

Pulmonary

- DLCO at least 60% of predicted

Other

- Not pregnant

- Negative pregnancy test

- HIV negative

- No severe psychiatric illness or mental deficiency that would preclude giving
informed consent or complying with study treatment

- No major illness or organ dysfunction that would preclude transplantation

- No other prior malignancy except basal cell or squamous cell skin cancer

PRIOR CONCURRENT THERAPY:

Biologic therapy

- See Disease Characteristics

Chemotherapy

- See Disease Characteristics

- No prior continuous busulfan for more than 6 months duration

Endocrine therapy

- Not specified

Radiotherapy

- Not specified

Surgery

- Not specified